Non-genomic estrogen/estrogen receptor α promotes cellular malignancy of immature ovarian teratoma in vitro

Journal of Cellular Physiology

Volumn 229, Issue 6, 2014, Pages 752-761

  Hung, Yao Ching ^a,b   Chang, Wei Chun ^a,b   Chen, Lu Min ^a,b   Chang, Ying Yi ^a,c   Wu, Ling Yu ^a   Chung, Wei Min ^a,b   Lin, Tze Yi ^a   Chen, Liang Chi ^a   Ma, Wen Lung ^a,b  

^a CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b CHINA MEDICAL UNIVERSITY   (Taiwan)

^c CHINA MEDICAL UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CD133 ANTIGEN; CELL MARKER; DIARYLPROPIONITRILE; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FOCAL ADHESION KINASE; FOCAL ADHESION KINASE RAS HOMOLOG GENE FAMILY MEMBER A; MICRORNA 21; MITOGEN ACTIVATED PROTEIN KINASE; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG;

ARTICLE; CELL FUNCTION; CELL INVASION; CELL MIGRATION; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; EPITHELIAL MESENCHYMAL TRANSITION; EPITHELIUM CELL; FEMALE; HUMAN; HUMAN CELL; IMMATURE OVARIAN TERATOMA; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MESENCHYME CELL; OVARY TERATOMA; POSITIVE FEEDBACK; PRIORITY JOURNAL; TRANSACTIVATION; TUMOR CELL LINE; UPREGULATION;

CELL LINE, TUMOR; CELL MOVEMENT; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; ESTROGENS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICRORNAS; NEOPLASM INVASIVENESS; OVARIAN NEOPLASMS; PHOSPHORYLATION; TERATOMA; TISSUE CULTURE TECHNIQUES; TUMOR STEM CELL ASSAY;

EID: 84894263670     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.24495     Document Type: Article

References (47)

1. Ahmed N, Abubaker K, Findlay J, Quinn M. 2010. Epithelial mesenchymal transition and cancer stem cell-like phenotypes facilitate chemoresistance in recurrent ovarian cancer. Curr Cancer Drug Targets 10:268-278.
2. Bronnum H, Andersen DC, Schneider M, Sandberg MB, Eskildsen T, Nielsen SB, Kalluri R, Sheikh SP. 2013. miR-21 promotes fibrogenic epithelial-to-mesenchymal transition of epicardial mesothelial cells involving programmed cell death 4 and Sprouty-1. PLoS ONE 8:e56280.
3. Carragher NO, Frame MC. 2004. Focal adhesion and actin dynamics: A place where kinases and proteases meet to promote invasion. Trends Cell Biol 14:241-249.
4. Cheng W, Chen L, Yang S, Han J, Zhai D, Ni J, Yu C, Cai Z. 2012. Puerarin suppresses proliferation of endometriotic stromal cells partly via the MAPK signaling pathway induced by 17ss-estradiol-BSA. PLoS ONE 7:e45529.
5. Chung W, Chang W, Chen L, Chang Y, Shyr J, Hung Y, Ma W. 2013. MicroRNA-21 promotes ovarian teratocarcinoma PA1 cell line by sustaining cancer stem/progenitor populations in vitro. Stem Cells Res Ther 4:88.
6. De Craene B, Berx G. 2013. Regulatory networks defining EMT during cancer initiation and progression. Nat Rev Cancer 13:97-110.
7. Ferretti V, Poitras C, Bergeron D, Coulombe B, Robert F, Blanchette M. 2007. PReMod: A database of genome-wide mammalian cis-regulatory module predictions. Nucleic Acids Res 35: (Database issue D122-126).
8. Graber R, Sumida C, Vallette G, Nunez EA. 1993. Rapid and long-term effects of 17 beta-estradiol on PIP2-phospholipase C-specific activity of MCF-7 cells. Cell Signal 5:181-186.
9. Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, Fitzgibbons PL, Francis G, Goldstein NS, Hayes M, Hicks DG, Lester S, Love R, Mangu PB, McShane L, Miller K, Osborne CK, Paik S, Perlmutter J, Rhodes A, Sasano H, Schwartz JN, Sweep FC, Taube S, Torlakovic EE, Valenstein P, Viale G, Visscher D, Wheeler T, Williams RB, Wittliff JL, Wolff AC. 2010. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). Arch Pathol Lab Med 134:e48-e72.
10. Hollenhorst PC. 2012. RAS/ERK pathway transcriptional regulation through ETS/AP-1 binding sites. Small GTPases 3:154-158.
11. Hubbard SA, Friel AM, Kumar B, Zhang L, Rueda BR, Gargett CE. 2009. Evidence for cancer stem cells in human endometrial carcinoma. Cancer Res 69:8241-8248.
12. Johnson AB, O'Malley BW. 2012. Steroid receptor coactivators 1, 2 and 3: Critical regulators of nuclear receptor activity and steroid receptor modulator (SRM)-based cancer therapy. Mol Cell Endocrinol 348:430-439.
13. Jung DE, Wen J, Oh T, Song SY. 2011. Differentially expressed microRNAs in pancreatic cancer stem cells. Pancreas 40:1180-1187.
14. Kalluri R, Weinberg RA. 2009. The basics of epithelial-mesenchymal transition. J Clin Invest 119:1420-1428.
15. Koshy M, Vijayananthan A, Vadiveloo V. 2005. Malignant ovarian mixed germ cell tumour: A rare combination. Biomed Imaging Interv J 1:e10.
16. Kousteni S, Han L, Chen JR, Almeida M, Plotkin LI, Bellido T, Manolagas SC. 2003. Kinase-mediated regulation of common transcription factors accounts for the bone-protective effects of sex steroids. J Clin Invest 111:1651-1664.
17. Ma WL, Hsu CL, Wu MH, Wu CT, Wu CC, Lai JJ, Jou YS, Chen CW, Yeh S, Chang C. 2008. Androgen receptor is a new potential therapeutic target for the treatment of hepatocellular carcinoma. Gastroenterology 135:e947-e955, e941-e945.
18. Ma WL, Yeh CC, Chang C. 2012a. Androgen and androgen receptor signals jamming monocyte/macrophage functions in premalignant phase of livers. BioMedicine 2:155-159.
19. Ma WL, Hsu CL, Yeh CC, Wu MH, Huang CK, Jeng LB, Hung YC, Lin TY, Yeh S, Chang C. 2012b. Hepatic androgen receptor suppresses hepatocellular carcinoma metastasis through modulation of cell migration and anoikis. Hepatology 56:176-185.
20. Mahdi H, Kumar S, Seward S, Semaan A, Batchu R, Lockhart D, Tamimi H, Munkarah AR. 2011. Prognostic impact of laterality in malignant ovarian germ cell tumors. Int J Gynecol Cancer 21:257-262.
21. McGowan-Jordan IJ, Speevak MD, Blakey D, Chevrette M. 1994. Suppression of tumorigenicity in human teratocarcinoma cell line PA-1 by introduction of chromosome 4. Cancer Res 54:2568-2572.
22. Migliaccio A, Di Domenico M, Castoria G, de Falco A, Bontempo P, Nola E, Auricchio F. 1996. Tyrosine kinase/p21ras/MAP-kinase pathway activation by estradiol-receptor complex in MCF-7 cells. EMBO J 15:1292-1300.
23. Migliaccio A, Piccolo D, Castoria G, Di Domenico M, Bilancio A, Lombardi M, Gong W, Beato M, Auricchio F. 1998. Activation of the Src/p21ras/Erk pathway by progesterone receptor via cross-talk with estrogen receptor. EMBO J 17:2008-2018.
24. Moniaga NC, Randall LM. 2011. Malignant mixed ovarian germ cell tumor with embryonal component. J Pediatr Adolesc Gynecol 24:e1-e3.
25. Mosselman S, Polman J, Dijkema R. 1996. ER beta: Identification and characterization of a novel human estrogen receptor. FEBS Lett 392:49-53.
26. Okoh V, Deoraj A, Roy D. 2011. Estrogen-induced reactive oxygen species-mediated signalings contribute to breast cancer. Biochim Biophys Acta 1815:115-133.
27. Oliveira FG, Dozortsev D, Diamond MP, Fracasso A, Abdelmassih S, Abdelmassih V, Goncalves SP, Abdelmassih R, Nagy ZP. 2004. Evidence of parthenogenetic origin of ovarian teratoma: Case report. Hum Reprod 19:1867-1870.
28. Pelletier AJ, Kunicki T, Ruggeri ZM, Quaranta V. 1995. The activation state of the integrin alpha IIb beta 3 affects outside-in signals leading to cell spreading and focal adhesion kinase phosphorylation. J Biol Chem 270:18133-18140.
29. Rybak AP, Ingram AJ, Tang D. 2013. Propagation of human prostate cancer stem-like cells occurs through EGFR-mediated ERK activation. PLoS ONE 8:e61716.
30. Salonen J, Butzow R, Palvimo JJ, Heikinheimo M, Heikinheimo O. 2009. Oestrogen receptors and small nuclear ring finger protein 4 (RNF4) in malignant ovarian germ cell tumours. Mol Cell Endocrinol 307:205-210.
31. Sampieri K, Fodde R. 2012. Cancer stem cells and metastasis. Semin Cancer Biol 22:187-193.
32. Sekiya S. 1995. Growth and differentiation of human germ cell tumors: A possible model of embryogenesis. Hum Cell 8:3-9.
33. Shirkoohi R. 2013. Epithelial mesenchymal transition from a natural gestational orchestration to a bizarre cancer disturbance. Cancer Sci 104:28-35.
34. Singh N, Liu G, Chakrabarty S. 2013. Isolation and characterization of calcium sensing receptor null cells: A highly malignant and drug resistant phenotype of colon cancer. Int J Cancer 132:1996-2005.
35. Sviracevic B, Sedlar S, Malobabic D, Cuk D. 2011. Mixed malignant germ cell tumor of ovary. Med Pregl 64:93-95.
36. Tanaka M, Abe T, Hara Y. 2009. Roles of focal adhesions and fibronectin-mediated cohesion in proliferation of confluent fibroblasts. J Cell Physiol 219:194-201.
37. Tewari K, Cappuccini F, Disaia PJ, Berman ML, Manetta A, Kohler MF. 2000. Malignant germ cell tumors of the ovary. Obstet Gynecol 95:128-133.
38. Tse JC, Kalluri R. 2007. Mechanisms of metastasis: Epithelial-to-mesenchymal transition and contribution of tumor microenvironment. J Cell Biochem 101:816-829.
39. Turner RT, Backup P, Sherman PJ, Hill E, Evans GL, Spelsberg TC. 1992. Mechanism of action of estrogen on intramembranous bone formation: Regulation of osteoblast differentiation and activity. Endocrinology 131:883-889.
40. Ulbright TM. 2005. Germ cell tumors of the gonads: A selective review emphasizing problems in differential diagnosis, newly appreciated, and controversial issues. Mod Pathol 18:S61-S79.
41. Walter P, Green S, Greene G, Krust A, Bornert JM, Jeltsch JM, Staub A, Jensen E, Scrace G, Waterfield M, Chambon P. 1985. Cloning of the human estrogen receptor cDNA. Proc Natl Acad Sci USA 82:7889-7893.
42. Wasim T, Majrroh A, Siddiq S. 2009. Comparison of clinical presentation of benign and malignant ovarian tumours. J Pak Med Assoc 59:18-21.
43. Ye LY, Wang JJ, Liu DR, Ding GP, Cao LP. 2012. Management of giant ovarian teratoma: A case series and review of the literature. Oncol Lett 4:672-676.
44. Yeh S, Lin HK, Kang HY, Thin TH, Lin MF, Chang C. 1999. From HER2/Neu signal cascade to androgen receptor and its coactivators: A novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells. Proc Natl Acad Sci USA 96:5458-5463.
45. Yu Z, Pestell TG, Lisanti MP, Pestell RG. 2012. Cancer stem cells. Int J Biochem Cell Biol 44:2144-2151.
46. Zavesky L, Jancarkova N, Kohoutova M. 2011. Ovarian cancer: Origin and factors involved in carcinogenesis with potential use in diagnosis, treatment and prognosis of the disease. Neoplasma 58:457-468.
47. Zhang S, Balch C, Chan MW, Lai HC, Matei D, Schilder JM, Yan PS, Huang TH, Nephew KP. 2008. Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer Res 68:4311-4320.